Nektar Therapeutics (NKTR) Tops Q3 EPS by 22c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $71.04 --0%
EPS Growth %: +26.6%
Financial Fact:
Net loss: -43.22M
Today's EPS Names:
CRMT, PKE, More
EPS Growth %: +26.6%
Financial Fact:
Net loss: -43.22M
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of $0.39, $0.22 better than the analyst estimate of $0.17. Revenue for the quarter came in at $152.9 million versus the consensus estimate of $114.62 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Solstice acquiring Element Solutions in $14.5B cash and stock deal
- Raymond James cuts Delta and JetBlue ratings ahead of Q2 earnings
- Lynx Equity on Lam Research (LRCX): 'Closing in on full valuation'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
